View in EDS HTML Full Text PDF Full Text

Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.

Saved in:
Bibliographic Details
Title: Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.
Authors: Radha Krishnan, Ramya Padmavathy (AUTHOR), Dzidowska, Monika (AUTHOR), Zheng, Danni (AUTHOR), Wong, Zoie Shui-Yee (AUTHOR), Buckley, Nicholas A. (AUTHOR), Raubenheimer, Jacques Eugene (AUTHOR)
Source: European Child & Adolescent Psychiatry. Nov2025, Vol. 34 Issue 11, p3331-3343. 13p.
Subjects: Drug therapy for psychoses, Risk assessment, Medical information storage & retrieval systems, Hyperlipidemia, Myocardial ischemia, CINAHL database, Hypertension, Long-term health care, Antipsychotic agents, Cardiovascular diseases risk factors, Risperidone, Descriptive statistics, Systematic reviews, MEDLINE, Hyperglycemia, Metabolic syndrome, Psychology information storage & retrieval systems, Weight gain, Thrombosis, Adolescence, Children
Abstract: Antipsychotics are known to cause cardiovascular and metabolic adverse effects, but there is less evidence for their use off-label, especially in children and adolescents. Such treatments may be administered over long durations. We conducted a systematic review to examine the cardiometabolic adverse effects of prolonged antipsychotic treatment in children and adolescents with non-psychotic disorders. We searched for randomised clinical trials and observational studies lasting for a year or more, examining the adverse outcomes of weight gain, hyperglycaemia, dyslipidaemia, hypertension, metabolic syndrome, ischaemic heart disease, and thrombosis. There were no randomised trials, and 15 observational studies involved 114,141 participants with mean age of 10.9 years (range of means 4.3–14.9 years). Twelve antipsychotics were covered but the majority (12 studies, 80%) examined risperidone. Using the vote counting method, long-term antipsychotic treatment was associated with weight gain (91.6% studies, n = 12), hyperglycaemia (100%, n = 6), dyslipidaemia (66.6%, n = 6), and metabolic syndrome (100%, n = 2). Hypertension was demonstrated in only one study (25%, n = 4), and none examined ischaemic heart disease or thrombosis. Studies exhibited moderate to high methodological quality. Prolonged exposure to antipsychotics during childhood may be associated with several metabolic adverse effects that could have long-term health impacts. Longer-term studies on a wider range of agents are required to clarify risks and develop appropriate strategies to mitigate them. Antipsychotic prescribing for children should be assessed on an individual basis, after weighing the benefits of therapy against the harms that may arise. Children need to be monitored for these metabolic effects, and early intervention is essential if adverse effects are severe. [ABSTRACT FROM AUTHOR]
Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 189593505
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Radha+Krishnan%2C+Ramya+Padmavathy%22">Radha Krishnan, Ramya Padmavathy</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dzidowska%2C+Monika%22">Dzidowska, Monika</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zheng%2C+Danni%22">Zheng, Danni</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wong%2C+Zoie+Shui-Yee%22">Wong, Zoie Shui-Yee</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Buckley%2C+Nicholas+A%2E%22">Buckley, Nicholas A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Raubenheimer%2C+Jacques+Eugene%22">Raubenheimer, Jacques Eugene</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Child+%26+Adolescent+Psychiatry%22">European Child & Adolescent Psychiatry</searchLink>. Nov2025, Vol. 34 Issue 11, p3331-3343. 13p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+therapy+for+psychoses%22">Drug therapy for psychoses</searchLink><br /><searchLink fieldCode="DE" term="%22Risk+assessment%22">Risk assessment</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+information+storage+%26+retrieval+systems%22">Medical information storage & retrieval systems</searchLink><br /><searchLink fieldCode="DE" term="%22Hyperlipidemia%22">Hyperlipidemia</searchLink><br /><searchLink fieldCode="DE" term="%22Myocardial+ischemia%22">Myocardial ischemia</searchLink><br /><searchLink fieldCode="DE" term="%22CINAHL+database%22">CINAHL database</searchLink><br /><searchLink fieldCode="DE" term="%22Hypertension%22">Hypertension</searchLink><br /><searchLink fieldCode="DE" term="%22Long-term+health+care%22">Long-term health care</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+diseases+risk+factors%22">Cardiovascular diseases risk factors</searchLink><br /><searchLink fieldCode="DE" term="%22Risperidone%22">Risperidone</searchLink><br /><searchLink fieldCode="DE" term="%22Descriptive+statistics%22">Descriptive statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Systematic+reviews%22">Systematic reviews</searchLink><br /><searchLink fieldCode="DE" term="%22MEDLINE%22">MEDLINE</searchLink><br /><searchLink fieldCode="DE" term="%22Hyperglycemia%22">Hyperglycemia</searchLink><br /><searchLink fieldCode="DE" term="%22Metabolic+syndrome%22">Metabolic syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Psychology+information+storage+%26+retrieval+systems%22">Psychology information storage & retrieval systems</searchLink><br /><searchLink fieldCode="DE" term="%22Weight+gain%22">Weight gain</searchLink><br /><searchLink fieldCode="DE" term="%22Thrombosis%22">Thrombosis</searchLink><br /><searchLink fieldCode="DE" term="%22Adolescence%22">Adolescence</searchLink><br /><searchLink fieldCode="DE" term="%22Children%22">Children</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Antipsychotics are known to cause cardiovascular and metabolic adverse effects, but there is less evidence for their use off-label, especially in children and adolescents. Such treatments may be administered over long durations. We conducted a systematic review to examine the cardiometabolic adverse effects of prolonged antipsychotic treatment in children and adolescents with non-psychotic disorders. We searched for randomised clinical trials and observational studies lasting for a year or more, examining the adverse outcomes of weight gain, hyperglycaemia, dyslipidaemia, hypertension, metabolic syndrome, ischaemic heart disease, and thrombosis. There were no randomised trials, and 15 observational studies involved 114,141 participants with mean age of 10.9 years (range of means 4.3–14.9 years). Twelve antipsychotics were covered but the majority (12 studies, 80%) examined risperidone. Using the vote counting method, long-term antipsychotic treatment was associated with weight gain (91.6% studies, n = 12), hyperglycaemia (100%, n = 6), dyslipidaemia (66.6%, n = 6), and metabolic syndrome (100%, n = 2). Hypertension was demonstrated in only one study (25%, n = 4), and none examined ischaemic heart disease or thrombosis. Studies exhibited moderate to high methodological quality. Prolonged exposure to antipsychotics during childhood may be associated with several metabolic adverse effects that could have long-term health impacts. Longer-term studies on a wider range of agents are required to clarify risks and develop appropriate strategies to mitigate them. Antipsychotic prescribing for children should be assessed on an individual basis, after weighing the benefits of therapy against the harms that may arise. Children need to be monitored for these metabolic effects, and early intervention is essential if adverse effects are severe. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=189593505
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00787-025-02771-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 13
        StartPage: 3331
    Subjects:
      – SubjectFull: Drug therapy for psychoses
        Type: general
      – SubjectFull: Risk assessment
        Type: general
      – SubjectFull: Medical information storage & retrieval systems
        Type: general
      – SubjectFull: Hyperlipidemia
        Type: general
      – SubjectFull: Myocardial ischemia
        Type: general
      – SubjectFull: CINAHL database
        Type: general
      – SubjectFull: Hypertension
        Type: general
      – SubjectFull: Long-term health care
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
      – SubjectFull: Cardiovascular diseases risk factors
        Type: general
      – SubjectFull: Risperidone
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Systematic reviews
        Type: general
      – SubjectFull: MEDLINE
        Type: general
      – SubjectFull: Hyperglycemia
        Type: general
      – SubjectFull: Metabolic syndrome
        Type: general
      – SubjectFull: Psychology information storage & retrieval systems
        Type: general
      – SubjectFull: Weight gain
        Type: general
      – SubjectFull: Thrombosis
        Type: general
      – SubjectFull: Adolescence
        Type: general
      – SubjectFull: Children
        Type: general
    Titles:
      – TitleFull: Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Radha Krishnan, Ramya Padmavathy
      – PersonEntity:
          Name:
            NameFull: Dzidowska, Monika
      – PersonEntity:
          Name:
            NameFull: Zheng, Danni
      – PersonEntity:
          Name:
            NameFull: Wong, Zoie Shui-Yee
      – PersonEntity:
          Name:
            NameFull: Buckley, Nicholas A.
      – PersonEntity:
          Name:
            NameFull: Raubenheimer, Jacques Eugene
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 10188827
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: European Child & Adolescent Psychiatry
              Type: main
ResultId 1